# Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)

> **NCT00073450** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 15 (actual)

## Conditions studied

- Carcinoma, Squamous Cell
- Head and Neck Neoplasms

## Interventions

- **DRUG:** Farnesyl Protein Transferase Inhibitor

## Key facts

- **NCT ID:** NCT00073450
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-09
- **Primary completion:** 2004-06
- **Final completion:** 2004-06
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2015-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00073450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00073450, "Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00073450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*